Subscribe To
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

Lilly Purchases Product Rights to Verve’s Lead Cardiovascular Programs from Beam Therapeutics BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the expansion of its relationship with Eli Lilly and Company (Lilly). Lilly has […] The post Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Program...
Read More
Posted: Oct 31 2023, 10:01
Author Name: forextv
Views: 042092